Incapacitating biochemical weapons science, technology, and policy for the 21st century

Nonproliferation Review

Volumn 13, Issue 2, 2006, Pages 151-188

  Pearson, Alan ^a  

^a NONE

Author keywords

Arms control; Biochemical weapons; Biological weapons; Chemical incapacitating agents; Chemical weapons; Fentanyl; Non lethal weapons

Indexed keywords

EID: 40049097259     PISSN: 10736700     EISSN: 17461766     Source Type: Journal    
DOI: 10.1080/10736700601012029     Document Type: Article

References (158)

1. National Research Council, Globalization, Biosecurity and the Future of the Life Sciences (Washington, DC: National Academies Press, 2006), p. 5
2. Elliot Kagan, “Bioregulators as Instruments of Terror,” Clinics in Laboratory Medicine. 21 (Sept. 2001), pp. 607-618
3. U.S. Army, Potential Military Chemical/Biological Agents and Compounds, Field Manual 3-11.9, Jan 10, 2005, p. 1-7, www.fas.org/irp/doddir/army/fm3-11-9.pdf
4. National Academies of Science, “Global Effort Needed to Anticipate and Prevent Potential Misuse of Advances in Life Science,” Press Release, Jan 31, 2006,
5. Kurt Kleiner, “US ‘unaware’ of emerging bioterror threats,” New Scientist.com News Service, Jan 31, 2006, www.newscientist.com/article.ns?id_/dn8656
6. Emily Singer, “Could Terrorists Hijack Your Brain?” Technology Review (Feb 1, 2006), www.technologyreview.com/read_article.aspx?id_/16221&ch_/biotech
7. Christopher J. Davis, “Nuclear Blindness: An Overview of the Biological Weapons Programs of the Former Soviet Union and Iraq,” Emerging Infectious Diseases. 5 (July-Aug. 1999), pp. 509-512
8. Committee for an Assessment of Non-Lethal Weapons Science and Technology, Naval Studies Board, National Research Council, An Assessment of Non-Lethal Weapons Science and Technology (Washington, DC: National Academies Press, 2003), p. 4.
9. Paul M. Wax, Charles E. Becker, and Steven C. Curry, “Unexpected ‘Gas’ Casualties in Moscow: A Medical Toxicology Perspective,” Annals of Emergency Medicine. 41 (Aug 2003) pp. 700-705
10. Neil Davison and Nick Lewer, Bradford Non-Lethal Weapons Research Project Research Report No 5, (Bradford, UK: Centre for Conflict Resolution, University of Bradford, May 2004), p. 39, www.bradford.ac.uk/acad/nlw/research_reports/docs/BNLWRPResearch ReportNo5_May04.pdf
11. Donald Voet, Biochemistry, 3rd ed. (New York: Wiley, 2004), p. 13.
12. Eva S. Istvan and Johann Deisenhofer, “Structural Mechanism for Statin Inhibition of HMG-CoA Reductase,” Science 292 (May 11, 2001), pp. 1160-1164
13. Bruce D. Roth, “The Discovery and Development of Atorvastatin, a Potent Novel Hypolipidemic Agent,” Progress in Medicinal Chemistry 40 (2002), pp. 1-22
14. IMS Health, ‘Leading Products by Global Sales, 2005,’
15. James S. Ketchum and Frederick R. Sidell, “Incapacitating Agents,” in Frederick R. Sidell, Ernest T. Takafugi, and David R. Franz, eds., Medical Aspects of Chemical and Biological Warfare, TMM series, Part I (Washington, DC: TMM Publications, 1997), p. 288
16. U.S. Army Field Manual 8-285, Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries, (Dec 22, 1995), P. 31,
17. James S. Ketchum and Frederick R. Sidell, “Incapacitating Agents,” p. 291
18. Caitriona McLeish, “The Governance of Dual-Use Technologies in Chemical Warfare,” M.Sc. dissertation, University of Sussex, 1997, pp. 55-65
19. Joan M. Lakoski, W. Bosseau Murray, and John M. Kenny, The Advantages and Limitations of Calmatives for Use as a Non-Lethal Technique (University Park, PA: Applied Research Laboratory, Pennsylvania State University, 2000), p. 48
20. Martin Furmanski, “Military Interest in Low-lethality Biochemical Agents: The Historical Interaction of Advocates, Experts, Pragmatists and Politicians,” (June 2005), p. 19, www.armscontrolcenter.org/cbw/symposium/papers/pdf/20050601_symposium_military_interest.pdf
21. Martin Furmanski, “Military Interest”
22. Malcolm Dando, “The UK’s Search for an Incapacitating (‘Non-Lethal’) Chemical Agent in the 1960s,” Bradford Science and Technology Report No 6 (Bradford, UK: Dept of Peace Studies, University of Bradford, Jan 2006)
23. Stockholm International Peace Research Institute, The Problem of Chemical and Biological Warfare (New York: Humanities Press, 1971), Vol. 2, p. 124
24. Stockholm International Peace Research Institute, The Problem of Chemical and Biological Warfare (New York: Humanities Press, 1971), Vol. 2, p 154.
25. Stockholm International Peace Research Institute, The Problem of Chemical and Biological Warfare (New York: Humanities Press, 1971), Vol. 2, p 265.
26. Stockholm International Peace Research Institute, The Problem of Chemical and Biological Warfare (New York: Humanities Press, 1971), Vol. 2, p 273.
27. Stockholm International Peace Research Institute, The Problem of Chemical and Biological Warfare (New York: Humanities Press, 1971), Vol. 5, pp. 47-49
28. Stockholm International Peace Research Institute, The Problem of Chemical and Biological Warfare (New York: Humanities Press, 1971), Vol. 5, pp 127-128
29. J. P Perry Robinson, “Disabling chemical weapons: some technical and historical aspects,” paper delivered to the Second Workshop of the Pugwash Study Group on Implementation of the CBW Conventions, Den Haag/Noordwijk, Netherlands, May 27-29, 1994.
30. U.S. Dept. of Defense, Directive 3000 3 Policy for Non-Lethal Weapons (July 9, 1996), p. 2.
31. Randy Copeland, “Joint Non-Lethal Weapons Program,” (June 2002), slide 2,
32. U.S. Marine Corps, “Joint Concept for Non-Lethal Weapons” (Jan 5, 1988), www.fas.org/man/dod-101/sys/land/docs/NONLETH.HTM
33. Naval Studies Board, An Assessment of Non-Lethal Weapons, pp. 12-15
34. Naval Studies Board, An Assessment of Non-Lethal Weapons, p. 20
35. Naval Studies Board, An Assessment of Non-Lethal Weapons, p 26
36. Naval Studies Board, An Assessment of Non-Lethal Weapons, p 27.
37. US/UK Non-Lethal Weapons (NLW)/Urban Operations Executive Seminar Assessment Report (Nov 30, 2000), p. 28,
38. U.S. Marine Corps, “Joint Concept”
39. Nick Lewer, “Introduction” in Nick Lewer, ed., The Future of Non-Lethal Weapons: Technologies, Operations, Ethics and Law (London/Portland, OR: Frank Cass, 2002), p. 1
40. Brian Rappert, Non-Lethal Weapons as Legitimizing Forces? (London/Portland, OR: Frank Cass, 2003), pp. 63-65
41. Brian Rappert, Non-Lethal Weapons as Legitimizing Forces? (London/Portland, OR: Frank Cass, 2003), pp 228-234.
42. B. Alexander, Future War: Non-Lethal Weapons in 21st Century Warfare (New York: St. Martin’s Press, 1999)
43. Graham T. Allison, Paul X. Kelley, and Richard L. Garwin, Non-lethal Weapons and Capabilities, Report of an Independent Task Force sponsored by the Council on Foreign Relations (New York: Council on Foreign Relations Press, 2004)
44. Malcolm Dando, A New Form of Warfare: The Rise of Non-Lethal Weapons (London: Brassey’s, 1996)
45. Douglas C. Lovelace and Steven Metz, Nonlethality and American Land Power (Carlisle, PA: Strategic Studies Institute, U.S. Army War College, 1998)
46. James S. Ketchum and Frederick R. Sidell, “Incapacitating Agents,” p. 295
47. David R. Franz, “Defense Against Toxin Weapons,” in Sidell,. Takafugi, and Franz, Medical Aspects of Chemical and Biological Warfare, p. 607.
48. Malcolm Dando and Martin Furmanski, “Midspectrum Incapacitant Programs,” in Mark Wheelis, Lajos Rozsa, and Malcolm Dando, eds., Deadly Cultures: Biological Weapons Since 1945 (Cambridge, MA: Harvard University Press, 2006), pp. 246-249.
49. Malcolm Dando and Martin Furmanski, “Midspectrum Incapacitant Programs,” in Mark Wheelis, Lajos Rozsa, and Malcolm Dando, eds., Deadly Cultures: Biological Weapons Since 1945 (Cambridge, MA: Harvard University Press, 2006), p. 243.
50. Jean Pascal Zanders, “Assessing the Risk of Chemical and Biological Weapons Proliferation to Terrorists,” Nonproliferation Review 6 (Fall 1999), pp. 23-25.
51. Martin Furmanski, “Military Interest,” p. 19.
52. John M. Kenny, “Human Effects Advisory Panel Program,” presentation at the Non-Lethal Defense IV Conference, sponsored by the National Defense Industrial Association, March 20-22, 2000, slide 23, www.dtic.mil/ndia/nld4/kenny.pdf
53. Lynn Klotz, Martin Furmanski, and Mark Wheelis, “Beware the Siren’s Song: Why ‘Non-Lethal’ Incapacitating Chemical Agents are Lethal,” Scientists Working Group on Biological and Chemical Weapons, March 2003, www.armscontrolcenter.org/cbw/wg/wg/wg2003_sirensong_non-lethal_chemical_agents.pdf
54. V.L. Klochikhin, A.A. Lushnikov, V.A. Zagaynov, A.V. Putilov, V.V. Selivanov, and M.A. Zatevakhin, “Principles of Modeling of the Scenario of Calmative Application in a Building With Deterred Hostages,” paper presented to the 3rd European Symposium on Non-Lethal Weapons, Stadthalle, Germany, May 10-12, 2005
55. L.E. Mather, “Clinical pharmacokinetics of fentanyl and its newer derivatives,” Clinical Pharmacokinetics. 8 (Sept Oct 1983), pp. 422-446
56. Center for Nonproliferation Studies, Chemical and Biological Weapons Nonproliferation Program, “The Moscow Theater Hostage Crisis: Incapacitants and Chemical Warfare,” (Nov 4, 2002) http://cns.miis.edu/pubs/week/02110b.htm
57. Paul M. Wax et al., “Unexpected ‘Gas’ Casualties.”
58. Tufts Center for the Study of Drug Development, “Outlook 2005,” p. 1, http://csdd.tufts.edu/InfoServices/OutlookPDFs/Outlook2005.pdf
59. David A.E. Shephard, “The changing pattern of anesthesia”, 1954-2004 A review based on the content of the Canadian Journal of Anesthesia in its first half-century,” Canadian Journal of Anesthesia 52 (March 2005), pp. 238-248.
60. Roche Pharmaceuticals, “Versed (midazolam HCl) Injection,” package insert,
61. Bedford Laboratories, “Propofol Injectable Emulsion 1%,” package insert, http://66.70.89.95/information/propofol.pdf
62. Alan S. Nies, “Principles of Therapeutics,” in Joel G. Hardman and Lee E. Limbird, eds., Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th ed. (New York: McGraw-Hill Professional, 2001), p. 51.
63. James S. Ketchum and Frederick R. Sidell “Incapacitating Agents,” p. 296.
64. Alan S. Nies, “Principles of Therapeutics,” p. 48.
65. V.L. Klochikhin et al., “Principles of Modeling,” p. 3.
66. Martin Furmanski, and Mark Wheelis, “Siren’s Song,” p. 4.
67. Guy Gugliotta, “U.S. Finds Hurdles in Search for Nonlethal Gas,” Washington Post, Nov 1, 2002, p. A30
68. Edgewood Research, Development & Engineering Center “Demonstration of Chemical Immobilizers,” Research Proposal, April 27, 1994, www.sunshine-project.org/incapacitants/jnlwdpdf/edgedemon.pdf
69. Joan M. Lakoski, W. Bosseau Murray, and John M. Kenny, Advantages and Disadvantages p. 5
70. Naval Studies Board, Assessment of Non-Lethal Weapons, pp. 22, 27
71. Naval Studies Board, Assessment of Non-Lethal Weapons p. 107
72. James S. Ketchum and Frederick R. Sidell, “Incapacitating Agents,” p. 288
73. Lynn Klotz et al., Beware the Siren’s Song.
74. Mark Wheelis and Malcolm Dando, “Neurobiology: A case study of the imminent militarization of biology,” International Review of the Red Cross. 87 (Sept 2005), p. 561
75. Malcolm R. Dando, “The Danger to the Chemical Weapons Convention from Incapacitating Chemicals,” First CWC Review Conference Paper Number 4 (Bradford, UK: Dept. of Peace Studies, University of Bradford, March 2003), pp. 5, 11.
76. Robert J. Lefkowitz, “Historical review: a brief history and personal retrospective of seven-transmembrane receptors,” Trends in Pharmacological Sciences. 25 (Aug 2004), pp. 413-422
77. Soloman H. Snyder and Gavril W. Pasternak, “Historical overview: Opioid receptors,” Trends in Pharmacological Sciences 24 (April 2003), pp. 198-205
78. Mark S. Boguski and Allan R. Jones, “Neurogenomics: at the intersection of neurobiology and genome sciences,” Nature Neuroscience 7. (May 2004), pp. 429-433
79. G. N. Grant, “Systems biology in neuroscience: Bridging genes to cognition,” Current Opinion in Neurobiology 13 (Oct. 2003), pp. 577-582.
80. Mark Wheelis, “Biotechnology and Biochemical Weapons,” Nonproliferation Review 9. (Spring 2002), pp. 48-53
81. Richard Kramer and Dalia Cohen, “Functional Genomics to New Drug Targets,” Nature Reviews Drug Discovery 3 (Nov 2004), pp. 965-972.
82. U.S. Food and Drug Administration, Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products (Washington DC, March 2004), www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
83. J.P. Perry Robinson, “Disabling Chemical Weapons: A Documentary Chronology of Events, 1945-2003,” Harvard Sussex Program, University of Sussex, Nov 1, 2003
84. David Brown and Peter Baker, “Moscow gas likely a potent narcotic,” Washington Post, Nov 11, 2002, p. A12
85. Naval Studies Board, Assessment of Non-Lethal Weapons, pp. 63-64.
86. P.L. Bailey, J. Wilbrink, P. Zwanikken, N.L. Pace, and T.H. Stanley, “Anesthetic induction with fentanyl,” Anesthesia and Analgesia 64 (Jan. 1985), pp. 48-53
87. James S. Ketchum and Frederick R. Sidell, “Incapacitating Agents,” p. 293
88. Taylor Pharmaceuticals, “Sufenta (Sufentanil Citrate) Injection,” package insert, www.akorn.com/documents/catalog/package_inserts/11098-050-01.pdf
89. W.F. Van Bever, C.J. Niemegeers, K.H. Schellekens, and P.A. Janssen, “N-4-Substituted 1-(2-arylethyl)-4-piperidinyl-N-phenylpropanamides, a novel series of extremely potent analgesics with unusually high safety margin,” Arzneimittel-forshung 26 (1976), pp. 1548-1551.
90. Thomas Stanley, “Human immobilization: Is the experience in Moscow just the beginning?” European Journal of Anaesthesiology 20 (June 2003), pp. 427-428.
91. Brian D. Anderson and Patrick M. Grant, “Dose Safety Margin Enhancement for Chemical Incapacitation and Less-Than-Lethal Targeting,” NIJ (National Institute of Justice) Final Report (Livermore, CA: Lawrence Livermore National Laboratory, Jan 1997)
92. Lois Pilant, “Less-than-Lethal Weapons: New Solutions for Law Enforcement,” Science and Technology, publication of the International Association of Chiefs of Police (Dec 1993), p. 3
93. C.J. Niemegeers, K.H. Schellekens, W.F. Van Bever, and P.A. Janssen, “Sufentanil, a very potent and extremely safe intravenous morphine-like compound in mice, rats and dogs,” Arzneimittel-forschung 26 (1976), pp. 1551-1556.
94. J. de Castro, A. Van de Water, L. Wouters, R. Xhonneux, R. Reneman, and B. Kay, “Comparative study of cardiovascular, neurological and metabolic side effects of 8 narcotics in dogs,” Act Anaesthesiologica Belgica 30 (March 1979), pp. 55-69
95. Karen S. Kearns, Brent Swenson, and Edward C. Ramsay, “Dosage trials with transmucosal carfentanil citrate in non-human primates,” Zoo Biology 18 (Jan 24, 2000), pp. 397-402.
96. L.E. Mather, A. Woodhouse, M.E. Ward, S.J. Farr, R.A. Rubsamen, and L.G. Eltherington, “Pulmonary administration of aerosolised fentanyl: Pharmacokinetic analysis of systemic delivery,” British Journal of Clinical Pharmacology 46 (July 1998), pp. 37-43.
97. David R. Franz, “Defense Against Toxin Weapons,” p. 607.
98. ERDEC, “Opioids”
99. Naval Studies Board, An Assessment of Non-Lethal Weapons, p. 27
100. Soloman H. Snyder and Gavril W. Pasternak, “Opioid receptors”, Robinson Chronology, Nov 13, 1990.
101. John Lancaster, “Pentagon, Justice Dept Set Plans for Sharing Non-Lethal Technology,” Washington Post, March 23, 1994, p. A3.
102. U.S. Dept. of Justice, National Institute of Justice, NIJ Research Plan 1995-1996 (Washington, DC: Dept of Justice, 1995), p. 20
103. Trent DePersia “Homeland Security Advanced Research Projects Agency,” Jan 25, 2004, www.hsarpabaa.com/main/HBCU/9_DePersia.pdf
104. Mark Wheelis, “‘Nonlethal’ Chemical Weapons: A Faustian Bargain”, Issues in Science and Technology (Spring 2003), www.issues.org/19.3/wheelis.htm
105. Naval Studies Board, An Assessment of Non-Lethal Weapons, p. 27.
106. Naval Studies Board, An Assessment of Non-Lethal Weapons, p. 107.
107. Neil Davison and Nick Lewer, Bradford Non-Lethal Weapons Research Project Research Report No 8, (Bradford, UK: Centre for Conflict Resolution, University of Bradford, March 2006), p. 52, www.brad.ac.uk/acad/nlw/research_reports/docs/BNLWRPResearchReportNo8_Mar06.pdf
108. Malcolm Dando, “Scientific and technological change and the future of the CWC: The problem of non-lethal weapons,” Disarmament Forum 4 (2002), p. 38, www.unidir.org/pdf/articles/pdf-art1824.pdf
109. Y. Chen, A. Mestek, J. Liu, J.A. Hurley and L. Yu, “Molecular cloning and expression of a muopioid receptor from rat brain,” Molecular Pharmacology. 44 (July 1993), pp. 8-12
110. C. Mollereau, M. Parmentier, P. Mailleux, J.L. Butour, C. Moisand, P. Chalon, D. Caput, G. Vassart, and J.C. Meunier, “ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization,” FEBS Letters 341 (March 14, 1994), pp. 33-38
111. I. Kitchen, S.J. Slowe, H.W.D. Matthes, and B. Kieffer, “Quantitative autoradiographic mapping of mu, delta and kappa-opioid receptors in knockout mice lacking the mu-opioid receptor gene,” Brain Research 778 (Dec 5, 1997), pp. 73-88
112. H.W. Matthes, R. Maldonado, F. Simonin, O. Valverde, S. Slowe, I. Kitchen, K. Befort, A. Dierich, M. Le Meur, P. Dolle, E. Tzavara, J. Hanoune, B.P. Roques, and B.L. Kieffer, “Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene,” Nature 383 (Oct 31, 1996), pp. 819-823.
113. R. Romberg, E. Sarton, L. Teppema, H.W. Matthes, B.L. Kieffer, and A. Dahan, “Comparison of morphine-6-glucuronid and morphine on respiratory depressant and antinociceptive responses in wild type and mu-opioid receptor deficient mice,” British Journal of Anaesthesia 91 (Dec 2003), pp. 862-870.
114. Slavko Bokan, John G. Breen, and Zvonko Orehovec, “An Evaluation of Bioregulators as Terrorism and Warfare Agents,” ASA Newsletter, 02-3, Issue 90 (June 28, 2002), p. 1, http://www.asanltr.com/newsletter/02-3/articles/023c.htm
115. Joan M. Lakoski et al. Advantages and Limitations, p. 5
116. Naval Studies Board, An Assessment of Non-Lethal Weapons, pp. 5, 79.
117. Robert Bunker, ed., Nonlethal Weapons: Terms and References, INSS Occasional Paper 15 (Colorado Springs: U.S. Air Force Academy, USAF Institute for National Security Affairs, Dec 1996), p. 10, http://www.usafa.af.mil/df/inss/OCP/ocp15.pdf
118. George Fenton, “The U.S. Dept. of Defense Joint Non-Lethal Weapons Program, March 2000 Overview,” presentation at the Non-Lethal Defense IV Conference, sponsored by the National Defense Industrial Association, March 20-22, 2000, slide 10, www.dtic.mil/ndia/nld4/fenton.pdf
119. Naval Studies Board, An Assessment of Non-Lethal Weapons, p. 24.
120. Robert J. Hegarty, “Joint Non-Lethal Weapons Program: Non-Lethal Mortar Cartridge (NLMC),” presentation at National Defense Industry Association 2003 Picatinny Chapter/PEO Mortars Conference, Oct 2003, www.sunshine-project.org/incapacitants/jnlwdpdf/usamort03.pdf
121. Camilo A. Sanchez, “Non-Lethal Airburst Munition(s) for Objective Individual Combat Weapon,” presentation at 2001 National Defense Industry Association Joint Services Small Arms Symposium, Aug 15, 2001
122. V.L. Klochikhin et al., “Principles of Modeling” p. 124.
123. V.L. Klochikhin et al., “Principles of Modeling” p. 125.
124. Neil Davison and Nick Lewer, Bradford Report No 5, p. 39, www.bradford.ac.uk/acad/nlw/research_reports/docs/BNLWRPResearchReportNo5_May04.pdf
125. Ladislav Hess, Jitka Schreiberova, and Josef Fusek, “Pharmacological non-lethal weapons,” paper presented to the 3rd European Symposium on Non-Lethal Weapons, Stadthalle, Germany, May 10-12, 2005.
126. NATO Research and Technology Organization, Non-Lethal Weapons and Future Peace Enforcement Operations, RTO-TR-SAS-040, Dec 2004, pp. 3-10,
127. Neil Davison and Nick Lewer, Bradford Report No 5, p. 39, www.bradford.ac.uk/acad/nlw/research_reports/docs/BNLWRPResearchReportNo5_May04.pdf
128. Guo Ji-wei and Xue-sen Yang, “Ultramicro, Nonlethal, and Reversible: Looking Ahead to Military Biotechnology,” Military Review. 85 (July-Aug. 2005), pp. 75-78, http://usacac.army.mil/CAC/milreview/download/English/JulAug05/yang.pdf
129. Till Manzke, Ulf Guenther, Evgeni G. Ponimaskin, Miriam Haller, Mathias Dutschmann, Stephan Schwarzacher, and Diethelm W. Richter, “5-HT4(a)Receptors Avert Opioid-Induced Breathing Depression Without Loss of Analgesia,” Science 301 (July 11, 2003), pp.226-229.
130. Helge Eilers and Mark A. Schumacher, “Opioid-induced Respiratory Depression: Are 5-HT4a Receptor Agonists the Cure?” Molecular Interventions 4 (Aug 2004), pp. 197-199.
131. Gavin J. Kilpatrick and Gary S. Tilbrook, “Drug development in anaesthesia: industrial perspective,” Current Opinion in Anaesthesiology 19 (Aug 2006), pp. 385-389.
132. Graham Pearson, Relevant Scientific and Technological Developments for the First CWC Review Conference: The BTWC Review Conference Experience, CWC Review Conference Paper No 1 (Bradford, UK: Dept. of Peace Studies, University of Bradford, Aug 2002), p. 5.
133. David P. Fidler, “The meaning of Moscow: ‘Non-lethal’ weapons and international law in the early 21st century.” International Review of the Red Cross 87 (Sept 2005), pp. 525-552.
134. David A. Koplow, “Tangled Up in Khaki and Blue: Lethal and Non-Lethal Weapons in Recent Confrontations,” Georgetown Journal of International Law. 36 (Spring 2005), p. 737.
135. Stephen J. Ledogar “My current instructions propose that riot control agents simply be defined out of the convention, not included. Committee on Foreign Relations, U.S. Senate, Chemical Weapons Ban Negotiation Issues, S HRG 102-719 (May 1, 1992), pp. 9-10.
136. Dept of the Navy, Office of the Judge Advocate General, International & Operational Law ivision, Preliminary legal review of proposed chemical-based non-lethal weapons, Nov 30, 1997, www.sunshine-project.org/incapacitants/jnlwdpdf/jagchemi.pdf
137. Judge Advocate General, Preliminary Review, p. 21.
138. Judge Advocate General, Preliminary Review, p. 22
139. Margaret-Anne Coppernoll, “The Nonlethal Weapons Debate,” Naval War College Review. 52 (Spring 1999), www.nwc.navy.mil/press/review/1999/spring/art5-sp9.htm
140. David A. Koplow, “Tangled Up,” pp. 737-738.
141. David P. Fidler, “The meaning of Moscow,” citing Articles 31.1 and 31.3(c) of the Vienna Convention on the Law of Treaties, May 23, 1969, UNTS Vol. 1155, p. 331.
142. Abram Chayes and Matthew Meselson, “Proposed Guidelines on the Status of Riot Control Agents and Other Toxic Chemicals Under the Chemical Weapons Convention,” Chemical Weapons Conventions Bulletin 35 (Harvard Sussex Program on CBW Armament and Arms Limitation, March 1997), pp. 13-17.
143. David P. Fidler, “The meaning of Moscow,” p. 538.
144. Robin M. Coupland “‘Calmatives’ and ‘Incapacitants’ Questions for humanitarian law brought by new means and methods of warfare with new effect,” paper presented to the Open Forum on the Chemical Weapons Convention-Challenges to the Chemical Weapons Ban, The Hague, Netherlands, May 1, 2003, p. 23
145. David P. Fidler, “‘Non-lethal’ weapons and international law: Three perspectives on the future,” Medicine, Conflict and Survival 17 (2001), pp. 199-201.
146. Peter W. Singer, Corporate Warriors: The Rise of the Privatized Military Industry (Ithaca, NY: Cornell University Press, 2003)
147. J. Patocka and J. Fusek, “Chemical Agents and Chemical Terrorism,” Central European Journal of Public Health 12, (2004), pp. S75-S77
148. S. Meselson and Julian P. Perry Robinson, “‘Non Lethal’ Weapons and Implementation of the Chemical and Biological Weapons Conventions,” paper delivered to the 20th Pugwash Workshop Study Group on the Implementation of the CBW Conventions, Geneva, Switzerland, Nov 8-9, 2003
149. Martin Furmanski, “Military Interest,” p. 16.
150. John Hart, Frida Kuhlau, and Jacqueline Simon, “Chemical and biological weapons developments and arms control,” in SIPRI Yearbook 2003: Armaments, Disarmament and International Security (Oxford: Oxford University Press, 2003), pp. 645-682
151. A Allison et al., Non-lethal Weapons and Capabilities, p. 32.
152. James B. Petro, Theodore R. Plasse, and Jack A. McNulty, “Biotechnology: Impact on Biological Warfare and Biodefense,” Biosecurity and Bioterrorism 1 (Sept. 2000), pp. 161-168.
153. Mark Wheelis, “Faustian Bargain,” p. 78.
154. A Allison et al., Non-lethal weapons, pp. 62-63.
155. Graham S. Pearson, New Scientific and Technological Developments of Relevance to the Fifth Review Conference, Bradford Review Conference Paper No 3 (Bradford, UK: University of Bradford, Dept of Peace Studies, 2001), p. 26, www.brad.ac.uk/acad/sbtwc/briefing/rcp3.pdf
156. John D. Steinbrunner, Elisa D. Harris, Nancy Gallagher, and Stacey Okutani, Controlling Dangerous Pathogens: A Prototype Protective Oversight System (University of Maryland, Center of International and Security Studies, Dec 2005), www.cissm.umd.edu/papers/files/pathogens_project_monograph.pdf
157. John D. Steinbrunner, Elisa D. Harris, Nancy Gallagher, and Stacey Okutani, Controlling Dangerous Pathogens: A Prototype Protective Oversight System (University of Maryland, Center of International and Security Studies, Dec 2005), www.biosecurityboard.gov
158. Feakin Bradford Non-Lethal Weapons Report No 3.